The new quality of productivity is the quality of advanced productivity in which innovation plays a leading role. In the field of medicine and health, the new quality productivity is reflected in the promotion of the quality and efficiency of medical services through scientific and technological innovation, industrial innovation, and institutional innovation.
The new situation breeds new opportunities
Medical science and technology innovation is a key area of scientific and technological innovation and has important strategic significance. The mainland has always attached great importance to medical science and technology innovation, and has made a series of plans and deployments around disease prevention, diagnosis, treatment and other technologies, increased investment, and formed a certain amount of research and development strength.
Promote breakthroughs in key core technologies at the "point". Innovative drugs and devices are important carriers of new quality productivity. Since the 18th National Congress of the Communist Party of China, the state has continued to increase its guiding investment in medical science and technology innovation, such as the establishment of major national science and technology projects for the creation of major new drugs, and the production of a number of chemical drugs, traditional Chinese medicines, and biotechnology drugs with significant clinical value, to promote breakthroughs in key core technologies.
Improve the industrial chain on the "line". Open up the upstream and downstream of the industrial chain, and promote the implementation and use of medical science and technology innovation products. In 2016, the drug marketing authorization holder system was piloted, in 2018, the medical device registrant system was piloted, in 2019, the filing system for drug clinical trial institutions was officially implemented, realizing the transformation from a recognition system to a filing system, and in 2020, the state formulated four types of procedures: breakthrough therapy drug procedures, conditional approval procedures, priority review and approval procedures, and special approval procedures, providing a "green channel" for the research and development of innovative drugs. Under the policy incentive, in recent years, the number of innovative drugs and devices approved for marketing in mainland China has reached new highs, and the medical insurance policy has gradually tilted towards innovative drugs and devices.
The overall layout on the "surface" is coordinated and developed. The mainland continues to plan the effective patent layout around key core technologies to reduce the risks that may arise in the process of industrial development. As early as 2013, the state launched a patent navigation pilot project to promote the guiding role of patent information analysis in technological innovation and industrial upgrading, realize the efficient integration of innovative technology resources, and enhance the scientificity of industrial development decision-making.
However, compared with developed countries, there is still a significant gap in the current level and ability of medical science and technology innovation in the mainland. The specific manifestations are: the output of high-level clinical research is small, the accumulation of medical science and technology research and development is relatively weak, the coordination between industry, university and research is insufficient, and the situation of some key core technologies being controlled by others has not been completely reversed; the deepening of the aging of the population and the continuous growth of per capita life expectancy have brought greater disease burden and unprecedented health challenges to the whole society, and the demand for more efficient and safer innovative drugs and devices has increased significantly, and there are higher requirements for the quality of medical and health services. As a result, new opportunities for medical science and technology innovation have also been born.
Innovation requires the whole chain to work in the same direction
Medical science and technology innovation is an important engine to promote the development of new quality productivity in the field of medicine and health, and its role runs through the whole chain of the medical and health industry. In this process, the clinical research of hospitals, the technological innovation of enterprises, and the optimization and coordination of the policy environment should work in the same direction to promote medical scientific and technological innovation to empower new quality productivity, and ultimately promote the high-quality development of the medical and health field.
From the front-end point of view, continuously strengthening independent research and development capabilities is the cornerstone of medical science and technology innovation. Hospitals should continue to strengthen the construction of national and local clinical medical research centers and high-level research hospitals, improve the quality and level of clinical research, and provide key clinical data for the research and development of new drugs and new treatments. Phase I clinical trials are the beginning of innovative drugs from basic experiments to human studies. With the increasing support for the establishment of phase I clinical research centers at the policy level, the number of phase I clinical research centers has gradually increased in recent years, and the forms have also been diversified, which has strengthened the clinical trial capacity of innovative drugs.
Enterprises should continue to strengthen the main position of scientific and technological innovation. Enterprises are not only the main participants in economic activities, but also the main promoters of technological progress, with both the willingness and the ability to innovate. In the future, enterprises can increase R&D investment and cultivate innovative talents by intervening in the R&D process at an early stage, so as to make innovative products closer to clinical promotion and application and the actual needs of the masses.
From the mid-end, deepening the combination of industry, education and research is the key to improving the efficiency of medical science and technology innovation. We should continue to promote the innovative allocation of production factors, and accelerate the industrialization process of scientific research achievements by establishing a close industry-university-research cooperation system to achieve complementary advantages, resource sharing and achievement sharing.
The cycle of medical science and technology research and transformation is much higher than that of other fields, and in this process, the incubation platform and pilot platform play the role of catalyst.
The incubation platform provides a series of resources and services, such as laboratory facilities, research equipment and other basic hardware support and professional services, which can help medical science and technology innovation projects accelerate the transition from the concept stage to the experimental and pilot stage, shorten the R&D cycle and reduce operating costs.
The pilot platform provides an experimental and verification environment for the R&D of innovative drugs and devices, which can test the production process, quality control, and stability of products under close to actual production conditions, promote the R&D of innovative drugs and devices to mature and go to the market, and improve the ability to transform scientific and technological achievements.
From the end point of view, product landing is the final link in the transformation of medical science and technology innovation achievements. Policy coordination is an important guarantee for the transformation of medical science and technology innovation achievements. Therefore, it is necessary to strengthen the efficient coordination, overall guidance and scientific supervision of government departments. For example, deepen the reform of the scientific and technological innovation system, innovate the management model, and promote the transformation of scientific and technological achievements The institutional mechanism has gradually matured, and the efficiency of the transformation of scientific and technological achievements has been further improved. Another example is the reasonable setting of medical insurance payment standards and the adjustment of the medical insurance drug list, which not only ensures the accessibility of innovative products, but also reduces the economic burden of patients, and can also ensure that new technologies and new products can obtain reasonable benefits, so as to promote the sustainable development of the pharmaceutical industry. Another example is to continuously improve the drug regulatory approval process, ensure the safety and effectiveness of innovative drugs and devices, and speed up the approval process, so that innovative products can benefit patients in a timely manner.
Text: Jin Chunlin and Wang Changying, Shanghai Health and Health Development Research Center
Editor: Lian Yi, Men Wenwen, Li Shiyao
Proofreading: Yang Zhenyu
Review: Qin Mingrui, Xu Bingnan